52
Participants
Start Date
October 1, 2019
Primary Completion Date
November 16, 2023
Study Completion Date
January 18, 2024
Itolizumab [Bmab 600]
EQ001
Columbia University Medical Center, Div of Nephrology, New York
Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx
Northwell Health / Division of Rheumatology, Great Neck
Northeast Clinical Research Center, LLC, Bethlehem
Georgia Nephrology, Lawrenceville
University of Florida, Division of Rheumatology, Gainesville
Omega Research Maitland, LLC, Orlando
SouthCoast Research Center Inc, Miami
Hope Clinical Trials, Miami
Centre for Rheumatology, Immunology and Arthritis, Fort Lauderdale
Clinical Research of West Florida - Tampa, Tampa
University of South Florida, Tampa
Clinical Site Partners Leesburg, LLC, Leesburg
Dallas Renal Group, Dallas
Prolato Clinical Research Center (PCRC), Houston
AKDHC Medical Research Services, LLC, Sun City
California Institute of Renal Research, Chula Vista
University of California San Diego Perlman Ambulatory Clinic, La Jolla
Clinical Research of West Florida - Clearwater, Clearwater
Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
Medanta - The Medicity Hospital, Gurugramam
MAX Super Specialty Hospital, New Delhi
Jawaharlal Nehru Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry
SP ZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi, Klinika Nefrologii, Hipertensjologii, Lodz
Miedzyleski Szpital Specjalistyczny w Warszawie, Oddzial Nefrologiczny i Stacja Dializ, Warsaw
Lead Sponsor
Biocon Limited
INDUSTRY
Equillium
INDUSTRY